{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,8,13]],"date-time":"2024-08-13T00:16:09Z","timestamp":1723508169667},"reference-count":17,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,8,12]]},"DOI":"10.7759\/cureus.66672","type":"journal-article","created":{"date-parts":[[2024,8,12]],"date-time":"2024-08-12T11:01:58Z","timestamp":1723460518000},"source":"Crossref","is-referenced-by-count":0,"title":["Visual Hallucinations With Arsenic Trioxide Therapy in Acute Promyelocytic Leukemia"],"prefix":"10.7759","author":[{"given":"Himil J","family":"Mahadevia","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ammar","family":"Al-Obaidi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Furha","family":"Cossor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1136\/pmj.79.933.391","article-title":"Acute and chronic arsenic toxicity","volume":"79","author":"Ratnaike RN","year":"2003","unstructured":"Ratnaike RN. Acute and chronic arsenic toxicity. Postgrad Med J. 2003, 79:391-6. 10.1136\/pmj.79.933.391","journal-title":"Postgrad Med J"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1177\/0960327107084539","article-title":"Arsenic neurotoxicity--a review","volume":"26","author":"Vahidnia A","year":"2007","unstructured":"Vahidnia A, van der Voet GB, de Wolff FA. Arsenic neurotoxicity--a review. Hum Exp Toxicol. 2007, 26:823-32. 10.1177\/0960327107084539","journal-title":"Hum Exp Toxicol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20143418","article-title":"Arsenic neurotoxicity in humans","volume":"20","author":"Mochizuki H","year":"2019","unstructured":"Mochizuki H. Arsenic neurotoxicity in humans. Int J Mol Sci. 2019, 20:3418. 10.3390\/ijms20143418","journal-title":"Int J Mol Sci"},{"key":"ref4","article-title":"Arsenic toxicity","author":"Kuivenhoven M","year":"2024","unstructured":"Kuivenhoven M, Mason K. Arsenic toxicity. StatPearls [Internet]. StatPearls Publishing, Treasure Island (FL); 2024."},{"key":"ref5","article-title":"A review of arsenic trioxide and acute promyelocytic leukemia","volume":"8","author":"Alimoghaddam K","year":"2014","unstructured":"Alimoghaddam K. A review of arsenic trioxide and acute promyelocytic leukemia. Int J Hematol Oncol Stem Cell Res. 2014, 8:44-54.","journal-title":"Int J Hematol Oncol Stem Cell Res"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2010.04.001","article-title":"Arsenic trioxide - an old drug rediscovered","volume":"24","author":"Emadi A","year":"2010","unstructured":"Emadi A, Gore SD. Arsenic trioxide - an old drug rediscovered. Blood Rev. 2010, 24:191-9. 10.1016\/j.blre.2010.04.001","journal-title":"Blood Rev"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-01-894980","article-title":"Management of acute promyelocytic leukemia: updated recommendations from an expert panel of the European LeukemiaNet","volume":"133","author":"Sanz MA","year":"2019","unstructured":"Sanz MA, Fenaux P, Tallman MS, et al.. Management of acute promyelocytic leukemia: updated recommendations from an expert panel of the European LeukemiaNet. Blood. 2019, 133:1630-43. 10.1182\/blood-2019-01-894980","journal-title":"Blood"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1300874","article-title":"Retinoic acid and arsenic trioxide for acute promyelocytic leukemia","volume":"369","author":"Lo-Coco F","year":"2013","unstructured":"Lo-Coco F, Avvisati G, Vignetti M, et al.. Retinoic acid and arsenic trioxide for acute promyelocytic leukemia. N Engl J Med. 2013, 369:111-21. 10.1056\/NEJMoa1300874","journal-title":"N Engl J Med"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(15)00193-X","article-title":"Arsenic trioxide and all-trans retinoic acid treatment for acute promyelocytic leukaemia in all risk groups (AML17): results of a randomised, controlled, phase 3 trial","volume":"16","author":"Burnett AK","year":"2015","unstructured":"Burnett AK, Russell NH, Hills RK, et al.. Arsenic trioxide and all-trans retinoic acid treatment for acute promyelocytic leukaemia in all risk groups (AML17): results of a randomised, controlled, phase 3 trial. Lancet Oncol. 2015, 16:1295-305. 10.1016\/S1470-2045(15)00193-X","journal-title":"Lancet Oncol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(15)00115-5","article-title":"Use of arsenic trioxide in remission induction and consolidation therapy for acute promyelocytic leukaemia in the Australasian Leukaemia and Lymphoma Group (ALLG) APML4 study: a non-randomised phase 2 trial","volume":"2","author":"Iland HJ","year":"2015","unstructured":"Iland HJ, Collins M, Bradstock K, et al.. Use of arsenic trioxide in remission induction and consolidation therapy for acute promyelocytic leukaemia in the Australasian Leukaemia and Lymphoma Group (ALLG) APML4 study: a non-randomised phase 2 trial. Lancet Haematol. 2015, 2:e357-66. 10.1016\/S2352-3026(15)00115-5","journal-title":"Lancet Haematol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1038\/ncb1717","article-title":"Arsenic degrades PML or PML-RARalpha through a SUMO-triggered RNF4\/ubiquitin-mediated pathway","volume":"10","author":"Lallemand-Breitenbach V","year":"2008","unstructured":"Lallemand-Breitenbach V, Jeanne M, Benhenda S, et al.. Arsenic degrades PML or PML-RARalpha through a SUMO-triggered RNF4\/ubiquitin-mediated pathway. Nat Cell Biol. 2008, 10:547-55. 10.1038\/ncb1717","journal-title":"Nat Cell Biol"},{"key":"ref12","article-title":"Mechanisms of action of arsenic trioxide","volume":"62","author":"Miller WH Jr","year":"2002","unstructured":"Miller WH Jr, Schipper HM, Lee JS, Singer J, Waxman S. Mechanisms of action of arsenic trioxide. Cancer Res. 2002, 62:3893-903.","journal-title":"Cancer Res"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1097\/PRA.0000000000000254","article-title":"An unusual case of acute psychosis with obsessive-compulsive features following arsenic poisoning","volume":"23","author":"Wu HE","year":"2017","unstructured":"Wu HE, Abdel-Gawad NM, Gharbaoui Y, Teixeira AL, Pigott TA. An unusual case of acute psychosis with obsessive-compulsive features following arsenic poisoning. J Psychiatr Pract. 2017, 23:382-5. 10.1097\/PRA.0000000000000254","journal-title":"J Psychiatr Pract"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.3390\/ijms221810077","article-title":"Molecular mechanism of arsenic-induced neurotoxicity including neuronal dysfunctions","volume":"22","author":"Thakur M","year":"2021","unstructured":"Thakur M, Rachamalla M, Niyogi S, Datusalia AK, Flora SJ. Molecular mechanism of arsenic-induced neurotoxicity including neuronal dysfunctions. Int J Mol Sci. 2021, 22:10077. 10.3390\/ijms221810077","journal-title":"Int J Mol Sci"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.14733","article-title":"Metabolism, toxicity and anticancer activities of arsenic compounds","volume":"8","author":"Khairul I","year":"2017","unstructured":"Khairul I, Wang QQ, Jiang YH, Wang C, Naranmandura H. Metabolism, toxicity and anticancer activities of arsenic compounds. Oncotarget. 2017, 8:23905-26. 10.18632\/oncotarget.14733","journal-title":"Oncotarget"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/j.taap.2020.115299","article-title":"Balance between the toxicity and anticancer activity of arsenic trioxide in treatment of acute promyelocytic leukemia","volume":"409","author":"Wang QQ","year":"2020","unstructured":"Wang QQ, Hua HY, Naranmandura H, Zhu HH. Balance between the toxicity and anticancer activity of arsenic trioxide in treatment of acute promyelocytic leukemia. Toxicol Appl Pharmacol. 2020, 409:115299. 10.1016\/j.taap.2020.115299","journal-title":"Toxicol Appl Pharmacol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/j.cjca.2012.04.004","article-title":"Cardiac conduction block at multiple levels caused by arsenic trioxide therapy","volume":"29","author":"Kathirgamanathan K","year":"2013","unstructured":"Kathirgamanathan K, Angaran P, Lazo-Langner A, Gula LJ. Cardiac conduction block at multiple levels caused by arsenic trioxide therapy. Can J Cardiol. 2013, 29:130.e5-6. 10.1016\/j.cjca.2012.04.004","journal-title":"Can J Cardiol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/252821-visual-hallucinations-with-arsenic-trioxide-therapy-in-acute-promyelocytic-leukemia","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,12]],"date-time":"2024-08-12T11:02:03Z","timestamp":1723460523000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/252821-visual-hallucinations-with-arsenic-trioxide-therapy-in-acute-promyelocytic-leukemia"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,12]]},"references-count":17,"URL":"https:\/\/doi.org\/10.7759\/cureus.66672","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,8,12]]}}}